This is a research study to find out if Qutenza 8% capsaicin topical system is safe and effective when treating subjects with lower back pain (LBP) that is caused by damage at or near the nerve's root in the lower back leg (lumbosacral radiculopathy) which is pain that can move all the way down the back of the leg. The pain may also start outside of the spinal cord, in the peripheral nerves and may also be felt all the way down the back of the leg (neuropathic LBP). Qutenza 8% capsaicin, the study drug, is currently FDA approved to treat nerve pain after a shingles outbreak in addition to a type of nerve pain in the feet associated with diabetes. In this study a maximum of four patches per visit (sized 14cm x 20 cm) will be used to deliver the Qutenza 8% capsaicin to the participants skin.
If a subject meets the qualifications for this study, in addition to their standard of care for their LBP, they can expect to have a total of 5 visits in a 12 month period. Each visit will require subjects to fill out several surveys and receive treatment patches for their LBP (your doctor will decide if participants will need to be retreated at each visit based on your symptoms). The study visits are estimated to take 90 minutes upwards to 120 minutes.

Start Date31 Jan 2025

Sponsor / Collaborator

Medical University of South Carolina

[+1]

100 Clinical Results associated with Capsaicin

100 Translational Medicine associated with Capsaicin

100 Patents (Medical) associated with Capsaicin

17,967

Literatures (Medical) associated with Capsaicin

01 May 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Investigation of the participation of the TRPV1 receptor in the irritant effect of dithranol in mice

Article

Author: Ferreira, Juliano ; Prudente, Arthur Silveira ; Luckemeyer, Débora Denardin ; Schran, Roberta Giusti ; da Silva, Ana Merian ; de Amorim Ferreira, Marcella

Dithranol is one of the most effective topical medications for treating plaque psoriasis. However, its clinical use is limited by irritative adverse reactions to the skin, such as oedema, erythema, and pruritus, caused by poorly understood mechanisms. Because TRPV1 activation mediates skin irritation caused by several drugs, we conducted blind and randomised experiments in male and female C57BL/6 mice to elucidate the role of TRPV1 in dithranol-induced irritation. Dithranol (0.01%-0.5%) or vehicle was applied topically to the right ear of the animals. Oedema, erythema, and pruritus were monitored from 2 hours to 6 days after application. Treatment with 0.5% dithranol caused oedema and erythema, but not pruritus, starting at 6 hours, reaching its highest point at 1 day, and persisting up to 6 days after treatment, mainly in male mice. The 0.1% dose induced erythema but not oedema. Interestingly, topical application of 1% capsaicin was shown to defunctionalise TRPV1-positive fibres and did not influence early irritation caused by dithranol (2 hours to 2 days). However, it increased the late phase of irritation (5-6 days). Similarly, salicylate did not reduce the early irritation caused by dithranol but also increased the late phase. Antagonism by SB366791 and 4-tert-butylcyclohexanol did not alter skin irritation. Our results suggest that, contrary to our initial hypothesis, TRPV1 appears to act protectively against skin irritation caused by dithranol, particularly in the late stage.

01 May 2025·FOOD HYDROCOLLOIDS

Novel capsaicin hollow salt constructed by nanoemulsion-spray drying strategy with enhanced antioxidant stability and stronger salty sensation

Author: Sun, Chenglong ; Huang, Shasha ; Ma, Yi ; Wang, Haitao ; Sun, Yuanda ; Tan, Mingqian

Designing new salt products to reduce sodium intake while maintaining the desired saltiness by optimizing the structure of salt has become a popular strategy in today's efforts to promote salt reductionTo meet this need and promote a more healthy diet, capsaicin (CAP) hollow salt (HS) with enhanced antioxidant stability and stronger salty sensation were prepared by nanoemulsion-spray drying strategy using a wet Maillard conjugate from whey protein isolate (WPI) and gum arabic (GA).The hollow salts prepared from nanoemulsions containing 15% (w/v) salt and 3% (w/v) WPI-GA conjugate showed better microstructure, water content, solubility, and angle of repose.The novel CAP-encapsulated hollow salt (CAP@HS) with 3% (w/v) WPI-GA conjugate exhibited a higher encapsulation rate of 72.16 ± 1.32% for CAP, along with good antioxidant ability and thermal ability.In addition, the CAP@HS demonstrated superior release in the intestinal fluid and exhibited high bioaccessibility during simulated digestion.It is worth mentioning that CAP@HS exhibited a higher fluorescence signal in the in vitro Na + retention assay conducted on porcine tongue, when compared to that of traditional salt and hollow salt.Combined with electronic tongue taste anal. and sensory evaluation, CAP@HS showed a stronger salty sensation.This will lead to new strategies for dual realization of sodium reduction and enhanced functionality for salt reduction products.

01 Apr 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Design of carbon materials with controllable morphology for efficient adsorption of Cu(II) ion and electromagnetic wave absorption

Author: Liu, Zhenxia ; Qu, Lele ; Yu, Liangmin ; Li, Xia ; Jiang, Xiaohui

By tailoring the morphol. structure of carbon materials, their effectiveness in adsorbing heavy-metal ions (Cu(II)) can be considerably enhanced.In this study, variations in reaction parameters and high-temperature pyrolysis facilitated the transformation of carbon material morphol. from spherical to hollow rod-like structures.The resulting carbon composites exhibited a uniform particle size and regular morphol.The adsorption performance of these carbon materials with varying morphologies was evaluated for Cu(II)-ions.Among them, the spherical adsorbent (P(CDB)-1@Cu) showed the highest adsorption efficiency, with a maximum capacity of 81.95 mg/g according to the Langmuir adsorption isotherm.To address the potential issue of secondary pollution caused by the release of adsorbed heavy-metal ions, the spent adsorbent was evaluated as an efficient electromagnetic-wave-absorption material.The results demonstrated that the spent adsorbent exhibited high-efficiency electromagnetic-wave-absorption properties.Notably, the spherical carbon material achieved a min. reflection loss (RL_min) of -44.57 dB and the broadest effective absorption bandwidth (EAB_max) of 5.76 GHz (12.24-18 GHz) at a thickness of only 2.0 mm.Thus, this work provides a solution to two major environmental pollution challenges: heavy-metal water contamination and electromagnetic-wave pollution.

News (Medical) associated with Capsaicin

24 Feb 2025

·www.prnewswire.com

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

TORONTO and AACHEN, Germany, Feb. 24, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain. Under the agreement, Searchlight Pharma ("Searchlight"), Apotex's specialty pharma division, will pursue marketing authorization for Qutenza and market and distribute Qutenza in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties. This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 branded, generic, and biosimilar pharmaceutical products. "Licensing the Canadian rights to Qutenza enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets," said Mark Nawacki, President of Searchlight. "This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care." "We have continuously developed Qutenza to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US," says Jan Adams, Chief Commercial Officer at Grünenthal. "Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain." Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities. About Qutenza ® In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit . Qutenza (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at . About Apotex and Searchlight Pharma Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets. Learn more about us at and at . About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group | Instagram: grunenthal Media contacts: Apotex: [email protected] Grünenthal Florian Dieckmann, Head Global Corporate Affairs +49 241 569-2555 [email protected] SOURCE Apotex Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalLicense out/inAcquisition

07 Nov 2024

·www.prnewswire.com

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures1, thus affecting more than 3 million people with surgical procedures per year in the U.S.2 QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025, and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data. AACHEN, Germany and MORRISTOWN, N.J., Nov. 7, 2024 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S. label. "Patients who undergo surgery and end up developing post-surgical neuropathic pain, may experience debilitating complications that often are not treated appropriately," says Lizandra Marcondes, M.D., PhD, Senior VP Medical Affairs & Drug Safety US, Averitas Pharma. "We believe QUTENZA® may be a clinically meaningful treatment option that could address the unmet needs of many patients in the United States who suffer from Post-surgical neuropathic pain and may not be satisfied with available oral, systemically acting medicines. We look forward to completing the Clinical Trial with the goal to file a supplemental new drug application to the U.S. Food and Drug Administration (FDA) in 2026, assuming positive data." AV001 is a randomized, double-blind 42-week trial including 410 patients who have been suffering from moderate to severe PSNP for at least six months. The primary endpoint of the trial is a reduction in the average pain intensity after 12 weeks compared to baseline. In addition, the trial assesses other outcomes including reduction in the average pain intensity after 42-weeks, progressive response over time with repeated treatment, reduction of the treatment area over several applications, and quality of life outcomes such as sleep interference, physical activity, anxiety, and depression. When completed, AV001 will be the first blinded randomized controlled trial in post-surgical neuropathic pain that evaluates the long-term treatment effects of a topical neuropathic pain treatment. "The completion of enrollment is an exciting milestone. With our current indications, adults with painful diabetic peripheral neuropathy of the feet and postherpetic neuralgia, we have advanced the trajectory of QUTENZA® in the U.S. by expanding access to a much-needed non-opioid therapy option for a large, underserved patient population," adds Marv Kelly, President Averitas Pharma. "By adding post-surgical neuropathic pain to the U.S. label if results are positive, we would have the potential to fill an unmet treatment need for additional patients in pain." When Grünenthal acquired the US-rights for Qutenza® in 2018, the US-label comprised the treatment of neuropathic pain associated with postherpetic neuralgia. Since then, Grünenthal re-launched the product and significantly increased patients' access to Qutenza®. In 2020, the U.S. FDA approved the product for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. With AV001, Grünenthal and Averitas hope to include another major indication in the field of peripheral neuropathic pain in the U.S. label. Topline results are anticipated in Q4 2025 and, assuming positive data, Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. About QUTENZA QUTENZA (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia, and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important U.S. safety information is available below and at . In Europe, QUTENZA is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. For further information please visit . About post-surgical neuropathic pain Post-surgical neuropathic pain (PSNP) is defined as chronic pain that develops after a surgical procedure and persists beyond the healing process, i.e., at least three months after the surgery. The pain is either localized to the surgical field or area of injury, projected to the innervation territory of a nerve situated in this area, or referred to a dermatome (after surgery/injury to deep somatic or visceral tissues).3 It is identified by symptoms of neuropathic nerve pain such as burning, stabbing or shooting pain, numbness, and changes to physical sensation or sensitivity to temperature or touch. PSNP occurs after approximately 10 percent of all surgical procedures1, thus affecting more than 3 million people with surgical procedures per year in the U.S.2 About Averitas Pharma, Inc. Averitas Pharma is a specialty pharmaceutical company dedicated to delivering innovative, effective, non-opioid pain management options to patients in the U.S. The company was formed in 2018 as a subsidiary of GRT U.S. Holding, Inc. and member of the Grünenthal Group. For more information, visit . Follow us on LinkedIn: About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal For further information, please contact: Christopher Jansen, Global Corporate Affairs Phone: +49 241 569-1428 [email protected] Florian Dieckmann, Head Global Corporate Affairs Phone: +49 241 569-2555 [email protected] IMPORTANT US-SAFETY INFORMATION Do not dispense QUTENZA to patients for self-administration or handling. Use only on dry, unbroken skin. Only physicians or healthcare professionals are to administer and handle QUTENZA, following the procedures in the label. Warnings and Precautions Severe Irritation: Whether applied directly or transferred accidentally from other surfaces, capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others. Do not use near eyes or mucous membranes, including face and scalp. Take protective measures, including wearing nitrile gloves and not touching items or surfaces that the patient may also touch. Flush irritated mucous membranes or eyes with water and provide supportive medical care for shortness of breath. Remove affected individuals from the vicinity of QUTENZA. Do not re-expose affected individuals to QUTENZA if respiratory irritation worsens or does not resolve. If skin not intended to be treated comes into contact with QUTENZA, apply Cleansing Gel and then wipe off with dry gauze. Thoroughly clean all areas and items exposed to QUTENZA and dispose of properly. Because aerosolization of capsaicin can occur with rapid removal, administer QUTENZA in a well-ventilated area, and remove gently and slowly, rolling the adhesive side inward. Application-Associated Pain: Patients may experience substantial procedural pain and burning upon application and following removal of QUTENZA. Prepare to treat acute pain during and following application with local cooling and/or appropriate analgesic medication. Increase in Blood Pressure: Transient increases in blood pressure may occur with QUTENZA treatment. Monitor blood pressure during and following treatment procedure and provide support for treatment-related pain. Patients with unstable or poorly controlled hypertension, or a recent history of cardiovascular or cerebrovascular events, may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment. Sensory Function: Reductions in sensory function (generally minor and temporary) have been reported following administration of QUTENZA. Assess for signs of sensory deterioration or loss prior to each application of QUTENZA. If sensory loss occurs, treatment should be reconsidered. Severe Application Site Burns: Full-thickness (third-degree) and deep partial-thickness (second-degree) burns have been reported following administration of QUTENZA. Cases of full-thickness (third-degree) burns, requiring hospitalization and skin grafting have been reported in patients who received QUTENZA for an unapproved indication and/or frequency of dosing at an application site where there had been prior skin trauma. Ensure that dosage and administration recommendations are followed. Adverse Reactions The most common adverse reactions (≥5% and > control group) in all controlled clinical trials are application site erythema, application site pain, and application site pruritus. To report SUSPECTED ADVERSE REACTIONS, contact Averitas Pharma, Inc. at 1-877-900-6479 or FDA at 1-800-FDA-1088 or . Please see full Prescribing Information. 1 Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain - update on incidence, risk factors and preventive treatment options. BJA Educ. 2022 May;22(5):190-196. doi: 10.1016/j.bjae.2021.11.008. Epub 2022 Feb 24. 2 (Accessed November 2024) 3 ICD 11 - SOURCE Grünenthal Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug Approval

22 Oct 2024

·pipelinereview.com

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

AACHEN, Germany I October 22, 2024 I Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025. “Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and transformative first-in-class therapy option to millions of patients suffering from chronic pain,” says Gillian Burgess, Head of Research, Grünenthal. “With a unique mechanism of action for treating chronic pain, these molecules have the potential to deliver robust pain relief combined with an improved safety profile compared to the available standard of care.” Pre-clinical data show that NOP receptor agonists have the potential to act as potent analgesics without abuse liability. 1 Leveraging the clinical data Grünenthal obtained during the development of its NOP receptor programme, Grünenthal now brings forward a candidate that shows best-in-class potency and selectivity for the NOP receptor. These properties are predicted to provide robust pain relief in a broad range of chronic pain indications without the serious central nervous system related side effects associated with available opioids. Grünenthal’s R&D pipeline includes multiple programmes across different stages, targets, modalities, and mechanisms of action to deliver innovative treatment options for patients suffering from pain and related diseases. Recently, a Phase I clinical trial with a Glucocorticoid Receptor Modulator (GRM) has been completed. The compound is developed to provide patients with a therapy option for chronic inflammatory diseases. In addition, Grünenthal is running a Phase III clinical trial with Qutenza ® (capsaicin) 8% topical system in post-surgical neuropathic pain, aiming to expand its label in the United States. A global Phase III programme investigating the efficacy, safety and tolerability of Resiniferatoxin in patients with painful osteoarthritis of the knee is currently ongoing. About the NOP Receptor The nociceptin (NOP) receptor is a G protein-coupled receptor whose natural ligand is the 17 amino acid neuropeptide known as nociceptin (N/OFQ). 2 NOP Receptor agonists have been shown to act as potent analgesics without abuse liability in pre-clinical models. 1 Although the NOP Receptor shares some sequence identity (~60%) with the opioid receptors μ-OP (MOP), κ-OP (KOP), and δ-OP (DOP), they possess little or no affinity for opioid peptides or morphine-like compounds. Likewise, opioid receptors possess little affinity towards NOP’s endogenous ligand nociceptin. 3 About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion. More information: https://www.grunenthal.com Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal 1 Lin AP, Ko MC. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci. 2013 Feb 20;4(2):214-24. doi: 10.1021/cn300124f. Epub 2012 Nov 6. PMID: 23421672; PMCID: PMC3582300. 2 Henderson G, McKnight AT (August 1997). “The orphan opioid receptor and its endogenous ligand– nociceptin/orphanin FQ”. Trends in Pharmacological Sciences. 18 (8): 293–300. doi:10.1016/S0165- 6147(97)90645-3. PMID 9277133. 3 Butour JL, Moisand C, Mazarguil H, Mollereau C, Meunier JC (February 1997). “Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids”. European Journal of Pharmacology. 321 (1): 97–103. doi:10.1016/S0014-2999(96)00919-3. PMID 9083791. SOURCE: Grünenthal Group

Phase 1Phase 3Phase 2

100 Deals associated with Capsaicin

External Link

KEGG	Wiki	ATC	Drug Bank
D00250	Capsaicin	M02AB01 N01BX04	DB06774

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	US	Averitas Pharma, Inc.Startup	17 Jul 2020
Neuralgia, Postherpetic	US	Averitas Pharma, Inc.Startup	16 Nov 2009
Neuralgia	CN	Changchun Pan-Chinapharm Co. Ltd.	24 Jan 2003
Pain	CN	Changchun Pan-Chinapharm Co. Ltd.	24 Jan 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral Nervous System Diseases	Phase 3	FR	Grünenthal GmbH	20 Oct 2023
Pain, Postoperative	Phase 3	US	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	FR	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	NL	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	PL	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	ES	Averitas Pharma, Inc.Startup	13 Jul 2021
Pain, Postoperative	Phase 3	GB	Averitas Pharma, Inc.Startup	13 Jul 2021
Breast Cancer	Phase 3	FR	Grünenthal GmbH	19 Mar 2019
Diabetic peripheral neuropathy	Phase 3	BE	Astellas Pharma, Inc.	01 Nov 2011
Diabetic peripheral neuropathy	Phase 3	CZ	Astellas Pharma, Inc.	01 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2024	Not Applicable	Dyspepsia \| Gastroesophageal Reflux \| Severe asthma	-	CAPSAICIN (GERD (+))	jqojukjspy(avrrvoaqhy) = pynuwjcrfe dmycjyqply (amluhwroru )	-	13 Oct 2024
NCT03722849 (CTgov)	Not Applicable	Refractory chronic cough	58	Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Chronic Cough Participant)	twivbywksa(uwpzklgozg) = rmzsgoszta tfrydizpew (wiojlfhtxj, pxxowtmkya - sbyukpgacw) View more	-	22 Aug 2024
				Functional Brain Imaging+Capsaicin+Adenosine Triphosphate (Healthy Control Participant)	twivbywksa(uwpzklgozg) = wcyudpwles tfrydizpew (wiojlfhtxj, znsprquzgy - wneandkyjl) View more
ADA2024	Not Applicable	Diabetic Neuropathies	-	High Concentration Capsaicin Topical System (HCCTS)	hnxbnqiail(lygzwqfdhk) = hidzcocrzx uohqbcmhql (iajvjxxtra ) View more	-	14 Jun 2024
NCT04918069 (Pubmed)	Phase 3	Chemotherapy-induced nausea and vomiting	160	Topical Capsaicin 0.075%	amnhfzafzu(erehqvisgn) = jfpbvmwmgc qosgrahelr (pibnzuzhuo ) View more	Positive	01 Jun 2024
				Placebo	crrwdmcdwg(fuqxkroemw) = ltgdtiwpzr srhocpkrfp (eppjdssidx ) View more
NCT05298202 (CTgov)	Phase 4	Heat Exhaustion	12	Hot environment+Capsaicin (Capsaicin Gel Application)	pqgsguwepv(ttptuhtnxu) = burtoqilgw mvkyyfrzjx (xrtpvddsxs, pptfofjvsg - fswwzgosui) View more	-	15 Mar 2024
				Control Gel (Hypoallergenic Gel Application)	pqgsguwepv(ttptuhtnxu) = girmxubesy mvkyyfrzjx (xrtpvddsxs, gvzaobqumf - ksrayetfis) View more
NCT04256733 (CTgov)	Early Phase 1	Cough	19	Supra-threshold (Supra-threshold Capsaicin)	bzbscbltmx(fizputoocq) = bpijiapkze wxycaewatf (idlsdbnakw, xkrozwazud - xnklfxndnh) View more	-	04 Mar 2024
				Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer (Sub-threshold Capsaicin)	bzbscbltmx(fizputoocq) = cnvnhdftjb wxycaewatf (idlsdbnakw, slaoocdlfe - ezwrluakkw) View more
EBCC2022	Not Applicable	Adjuvant	35	Capsaicin patch 179 mg	eavppanwrt(cjmpyltylp) = gokutfomyn udvlbujdyy (khhhpgmslb ) View more	-	17 Nov 2022
UEGW2022	Not Applicable	TRPV1 agonist	51	Capsaicin 10Õ¼m	uejjqfjoxy(vwnroxffvu) = smoauuygrv sohtumkkit (amiairzepd ) View more	Positive	09 Oct 2022
				Placebo	uejjqfjoxy(vwnroxffvu) = zchfhldnjk sohtumkkit (amiairzepd )
NCT03429049 (CTgov)	Phase 3	Osteoarthritis, Knee	332	Placebo (Placebo)	orjxsijbdm(xwkcbwrzsk) = qphbvumwls xvnpfptsil (ixkucrbntb, yqhyiwqjuo - ebqvkubaem) View more	-	08 Apr 2022
				CNTX-4975-05 (CNTX-4975-05)	orjxsijbdm(xwkcbwrzsk) = hjuumzmieh xvnpfptsil (ixkucrbntb, fymrhhyewl - lcwinyxyid) View more
UEGW2021	Not Applicable	Pain	-	Capsaicin perfusion	jsoutzvbmv(vnuhzgswjm) = impaired recovery of the baseline impedance compared to saline-treated controls nsojnxncqb (pdwfnuitqy )	-	02 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis